Recent Quotes

My Watchlist

Indicators

Markets:

Overview

News

Currencies

International

Treasuries

Sarepta Therapeutics, Inc. - Common Stock (NQ:SRPT)

23.77 +6.16 (+34.98%)

Streaming Delayed Price Updated: 4:00 PM EDT, Mar 25, 2026 Add to My Watchlist

Price and Volume

Detailed Quote

Volume	17,056,910
Open	19.76
Bid (Size)	23.60 (500)
Ask (Size)	23.61 (100)
Prev. Close	17.61
Today's Range	19.67 - 23.85
52wk Range	10.41 - 76.67
Shares Outstanding	93,148,652
Dividend Yield	N/A

Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News

Let's have a look at the top gainers and losers one hour before the close of the markets of today's session. ↗

Today 16:00 EDT

Via Chartmill

Wednesday's session: top gainers and losers ↗

Today 13:30 EDT

Via Chartmill

Performance

YTD	+11.5%	+11.5%
1 Month	+31.2%	+31.2%
3 Month	+8.0%	+8.0%
6 Month	+32.6%	+32.6%
1 Year	-68.9%	-68.9%

More News

Which stocks are gapping on Wednesday? ↗

Today 11:30 EDT

Via Chartmill

Sarepta Therapeutics (SRPT) at a Crossroads: A 2026 Deep Dive into the Future of Genetic Medicine

Today 9:36 EDT

Via Finterra

Sarepta Therapeutics (NASDAQ:SRPT) Posts Q4 Revenue Beat Amid Deep Losses and Major Charges ↗

February 25, 2026

Via Chartmill

Why Did SRPT Stock Rise 6% In Pre-Market Today? ↗

January 26, 2026

Via Stocktwits

Sarepta Announces First Clinical Data from siRNA Pipeline Targeting FSHD1 and DM1

Today 8:05 EDT

From Sarepta Therapeutics, Inc.

Via Business Wire

Sarepta to Share First Clinical Data from siRNA Pipeline Targeting FSHD1 and DM1

March 24, 2026

From Sarepta Therapeutics, Inc.

Via Business Wire

2 Beaten-Down Stocks That Still Aren't Worth Buying ↗

March 21, 2026

Via The Motley Fool

Sarepta Provides Regulatory Update on AMONDYS 45® and VYONDYS 53®

March 19, 2026

From Sarepta Therapeutics, Inc.

Via Business Wire

Sarepta Shares Rise As Company Begins Enrollment In Gene Therapy Safety Enhancement Study ↗

March 16, 2026

Via Stocktwits

Sarepta Announces that Screening and Enrollment are Underway in ENDEAVOR Cohort 8 to Evaluate Enhanced Immunosuppression Regimen as Part of ELEVIDYS Gene Therapy for Non-Ambulant Individuals with Duchenne

March 16, 2026

From Sarepta Therapeutics, Inc.

Via Business Wire

Sarepta Therapeutics Announces Call for Applications for the 9th Annual Route 79, The Duchenne Scholarship Program

February 27, 2026

From Sarepta Therapeutics, Inc.

Via Business Wire

Sarepta Therapeutics to Present New Long-Term and Safety Data Across Gene Therapy and Exon-Skipping Programs at 2026 Muscular Dystrophy Association Clinical & Scientific Congress

February 26, 2026

From Sarepta Therapeutics, Inc.

Via Business Wire

Nasdaq, S&P 500 Futures Tread Caution On Nvidia’s China Risk: Why NFLX, WBD, AAPL, CRM, AI, LRMR Are On Traders' Radar Today ↗

February 26, 2026

Via Stocktwits

Sarepta Stock Dips After Hours: DMD Drug Blow And CEO Exit Eclipse Q4 Revenue Beat ↗

February 25, 2026

Via Stocktwits

Sarepta (SRPT) Q4 2025 Earnings Call Transcript ↗

February 25, 2026

Via The Motley Fool

Sarepta Therapeutics Announces Fourth Quarter and Full-Year 2025 Financial Results and Recent Corporate Developments

February 25, 2026

From Sarepta Therapeutics, Inc.

Via Business Wire

Sarepta Therapeutics Announces Commercial Launch of ELEVIDYS in Japan

February 24, 2026

From Sarepta Therapeutics, Inc.

Via Business Wire

Sarepta Therapeutics to Present at the TD Cowen 46th Annual Health Care Conference

February 24, 2026

From Sarepta Therapeutics, Inc.

Via Business Wire

SRPT Stock Snaps Hot Winning Streak Ahead Of Q4 Print — What Bear Positioning And Big Money Are Signaling ↗

February 24, 2026

Via Stocktwits

Sarepta Hits Fresh Hurdle As Court Revives Patent Lawsuit With Regenxbio Over Muscular Disorder Therapy ↗

February 20, 2026

Via Stocktwits

Sarepta Therapeutics to Announce Fourth Quarter and Full-Year 2025 Financial Results

February 11, 2026

From Sarepta Therapeutics, Inc.

Via Business Wire

Sarepta Therapeutics Announces Approval of Clinical Trial Application for SRP-1005, Its Investigational Treatment for Huntington’s Disease

February 04, 2026

From Sarepta Therapeutics, Inc.

Via Business Wire

Sarepta Announces Positive Topline Three-Year EMBARK Results Showing ELEVIDYS Significantly Slows Disease Progression on Key Functional Measures in Ambulatory Duchenne Patients

January 26, 2026

From Sarepta Therapeutics, Inc.

Via Business Wire

Frequently Asked Questions

Is Sarepta Therapeutics, Inc. - Common Stock publicly traded?

Yes, Sarepta Therapeutics, Inc. - Common Stock is publicly traded.

What exchange does Sarepta Therapeutics, Inc. - Common Stock trade on?

Sarepta Therapeutics, Inc. - Common Stock trades on the Nasdaq Stock Market

What is the ticker symbol for Sarepta Therapeutics, Inc. - Common Stock?

The ticker symbol for Sarepta Therapeutics, Inc. - Common Stock is SRPT on the Nasdaq Stock Market

What is the current price of Sarepta Therapeutics, Inc. - Common Stock?

The current price of Sarepta Therapeutics, Inc. - Common Stock is 23.77

When was Sarepta Therapeutics, Inc. - Common Stock last traded?

The last trade of Sarepta Therapeutics, Inc. - Common Stock was at 03/25/26 04:00 PM ET

What is the market capitalization of Sarepta Therapeutics, Inc. - Common Stock?

The market capitalization of Sarepta Therapeutics, Inc. - Common Stock is 2.21B

How many shares of Sarepta Therapeutics, Inc. - Common Stock are outstanding?

Sarepta Therapeutics, Inc. - Common Stock has 2B shares outstanding.

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.